Pawaskar Manjiri D, Joish Vijay N, Camacho Fabian T, Rasu Rafia S, Balkrishnan Rajesh
Department of Pharmacy Practice and Administration, Ohio State University College of Pharmacy, Columbus, OH, USA.
J Med Econ. 2008;11(1):41-56. doi: 10.3111/13696990701817491.
Patients with insomnia are likely to have other co-morbidities that could affect pharmacotherapeutic choices. This study examined the prevalence and impact of co-morbidities on the pharmacological treatment of insomnia.
A retrospective data analysis of the National Ambulatory Medical Care Survey from 1995 to 2004, comprising patients with a diagnosis of insomnia, was conducted. Multivariate logistic regression models were used to predict the impact of co-morbidities on pharmacotherapy for insomnia.
A total of 5,487 unweighted patient visits with insomnia were identified, representing 161.4 million patients in the US. Approximately 38% of these patients had at least one co-morbid condition. Patients with mental co-morbidities, especially anxiety, had decreased likelihood of receiving pharmacotherapy for insomnia.
Mental co-morbidities such as episodic mood disorder, anxiety and depression are prevalent in patients with insomnia. However, many co-morbid patients do not receive pharmacological therapy specific for insomnia.
失眠患者可能伴有其他共病，这可能会影响药物治疗的选择。本研究调查了共病的患病率及其对失眠药物治疗的影响。
对1995年至2004年美国国家门诊医疗调查中诊断为失眠的患者进行回顾性数据分析。采用多变量逻辑回归模型预测共病对失眠药物治疗的影响。
共确定了5487例未加权的失眠患者就诊病例，代表美国1.614亿患者。其中约38%的患者至少有一种共病。伴有精神共病的患者，尤其是焦虑症患者，接受失眠药物治疗的可能性降低。
发作性情绪障碍、焦虑和抑郁等精神共病在失眠患者中很常见。然而，许多共病患者未接受针对失眠的药物治疗。
